The lesson
Sell a technical white paper with a short market shift, a bottleneck, and the named system that answers it.
The page opens with the label “WHITE PAPER,” the date “April 1, 2023,” the title, and two CTAs: “See more” and “Download.” The body starts with the shift that biologics accounted for more new drug approvals than small molecules in 2022, then names the pressure on CHO-based bioproduction systems. It narrows to expression vector design as the lagging area, then introduces Asimov’s CHO Edge system with a GS knock-out CHO host, a Fut8/GS double knock-out option, a proprietary hyperactive transposase, more than 2,500 characterized genetic elements, and Kernel software. The close adds performance and commercial terms, including titers of 5–10 g/L, a four-month CLD timeline, and a free campaign condition if a generated RCB expresses a MAb at <4 g/L.
Don't copy Asimov's CHO Edge details, genetic element counts, or commercial offer. Keep the structure of market change, technical bottleneck, system preview, and direct download CTA.
Tell us what you want to make. We’ll talk through how to put these ideas to work for your brand.